ultevursen – Patient Worthy

Daniel de Boer. Photo courtesy of: ProQR and FTI Consulting

INTERVIEW: How ProQR’s Sirius and Celeste Studies Could Change the Therapeutic Landscape for USH2A-Mediated RP and Usher Syndrome (Pt. 2)

Post author:Jessica Lynn
Post published:February 15, 2022
Post category:Retinitis pigmentosa usher syndrome

If you would like to read the first part of this interview, please take a look at Part 1 here. In the first part of the interview, I spoke with…

Daniel de Boer. Photo courtesy of: ProQR and FTI Consulting

INTERVIEW: How ProQR’s Sirius and Celeste Studies Could Change the Therapeutic Landscape for USH2A-Mediated RP and Usher Syndrome (Pt. 1)

Post author:Jessica Lynn
Post published:February 14, 2022
Post category:Retinitis pigmentosa usher syndrome

Clinical trials, drug development, and medical research have the potential to change the therapeutic landscape for patients with a wide variety of conditions. At ProQR, founder and CEO Daniel de…

INTERVIEW: How ProQR’s Sirius and Celeste Studies Could Change the Therapeutic Landscape for USH2A-Mediated RP and Usher Syndrome (Pt. 2)

INTERVIEW: How ProQR’s Sirius and Celeste Studies Could Change the Therapeutic Landscape for USH2A-Mediated RP and Usher Syndrome (Pt. 1)

Let’s Work Together!

Keep Up to Date

Learn More